Evogene (EVGN)
(Delayed Data from NSDQ)
$0.65 USD
+0.03 (4.02%)
Updated Apr 29, 2024 03:58 PM ET
After-Market: $0.66 +0.01 (1.51%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
EVGN 0.65 +0.03(4.02%)
Will EVGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EVGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EVGN
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
EVGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
Here's Why Evogene (EVGN) is a Great Momentum Stock to Buy
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
Other News for EVGN
EverGen Infrastructure Reports Q4 & Year End 2023 Results
EverGen Reports Growth Amid Expansions
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
Analysts Offer Insights on Healthcare Companies: Evogene (EVGN), Edwards Lifesciences (EW) and Nurix Therapeutics (NRIX)